IE
ACHL

Israel Englander’s Achilles Therapeutics ACHL Stock Holding History

Israel Englander’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-19,117
Closed -$23.9K – 6674
2024
Q1 		$23.9K Sell
19,117
-11,832
-38% -$12.8K ﹤0.01% 5799
2023
Q4 		$27.5K Buy
30,949
+14,671
+90% +$12.6K ﹤0.01% 5587
2023
Q3 		$14.8K Sell
16,278
-22,091
-58% -$21K ﹤0.01% 5702
2023
Q2 		$36.3K Sell
38,369
-88,880
-70% -$84.4K ﹤0.01% 5536
2023
Q1 		$122K Buy
127,249
+45,494
+56% +$49.3K ﹤0.01% 5352
2022
Q4 		$74K Buy
+81,755
New +$138K ﹤0.01% 5672
2022
Q1 		– Sell
-26,423
Closed -$132K – 7625
2021
Q4 		$132K Sell
26,423
-119,106
-82% -$721K ﹤0.01% 6137
2021
Q3 		$1.13M Sell
145,529
-50,615
-26% -$333K ﹤0.01% 4536
2021
Q2 		$1.92M Sell
196,144
-6,641
-3% -$90K ﹤0.01% 4007
2021
Q1 		$3.36M Buy
+202,785
New +$3.36M ﹤0.01% 3018

Other funds holding ACHL

SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Israel Englander's ACHL Position: Q2 2024 in Review

Israel Englander sold out of Achilles Therapeutics (ACHL) in Q2 2024, closing a stake of 19,117 shares — an estimated $23.9K sold.

Israel Englander first reported a position in ACHL in Q1 2021 and held it in 10 quarters. The position peaked at $3.36M in Q1 2021. 27 funds tracked by Wall St. Rank hold ACHL as of Q2 2024.

  • Israel Englander reported no remaining Achilles Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Israel Englander sold 19,117 Achilles Therapeutics shares in Q2 2024, an estimated $23.9K.
  • Israel Englander first reported a position in Achilles Therapeutics in Q1 2021 and held it in 10 quarters.
  • Israel Englander's Achilles Therapeutics position peaked at $3.36M in Q1 2021.
  • 27 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q2 2024.

Based on Millennium Management's 13F filing for Q2 2024, filed 14 Aug 2024.